Figure 1.
A) Kaplan-Meier Analysis of overall survival and disease specific survival among patients with at least one mutation in ATM, RB1, FANCC (Mutant) versus those without a mutation in these genes (Wild Type). All patients received neoadjuvant chemotherapy with a cisplatin backbone (MVAC or Gem/Cis). B) 5-year overall survival (OS) and disease specific survival (DSS) rates for combined and individual cohorts with 95% confidence intervals represented in parenthesis.